Evidence map›Paper›PMID 24684595›Full record

ReviewAntioxidants & redox signaling2014

The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.

Lawrence D Horwitz, Marcus A Horwitz

Open access · hybridAbstract readReview
In one paragraph

Review in Antioxidants & redox signaling, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. PPE37 Is Essential forInfection and immunity · 2019
    Article
  4. A reevaluation of iron binding by Mycobactin J.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2018
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Lawrence D Horwitz1 Division of Cardiology, Department of Medicine, University of Colorado Health Sciences Center , Denver, Colorado.
Marcus A Horwitz
University of California, Los Angeles · USUniversity of Colorado Health · US

Funding

Characterization of the M. tuberculosis phagosomeR01HL077000 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HORWITZ, MARCUS AARON · 2003 to 2007
$2.5M
IRON-MEDIATED CARDIOVASCULAR INJURYR01HL055291 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI HORWITZ, LAWRENCE · 1996 to 2006
$2.1M
MYCOBACTERIUM TUBERCULOSIS PHAGOSOMER01AI035275 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HORWITZ, MARCUS AARON · 1993 to 2002
$1.0M
EXOCHELINS, TUBERCULOSIS, AND AIDSR01AI033790 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HORWITZ, MARCUS AARON · 1993 to 1995
–
NHLBI NIH HHS HL077000NHLBI NIH HHS HL55291NHLBI NIH HHS R01 HL077000NIAID NIH HHS AI33790NIAID NIH HHS AI35725
6 · The paper itself

Abstract

significanceExochelins are lipid- and water-soluble siderophores of Mycobacterium tuberculosis with unique properties that endow them with exceptional pharmacologic utility. Exochelins can be utilized as probes to decipher the role of iron in normal and pathological states, and, since they rapidly cross cell membranes and chelate intracellular iron with little or no toxicity, exochelins are potentially useful for the treatment of a number of iron-dependent pathological phenomena. RECENT ADVANCES: In animal models, exochelins have been demonstrated to have promise for the treatment of transfusion-related iron overload, restenosis after coronary artery angioplasty, cancer, and oxidative injury associated with acute myocardial infarction and transplantation. CRITICAL ISSUES: To be clinically effective, iron chelators should be able to rapidly enter cells and chelate iron at key intracellular sites. Desferri-exochelins, and other lipid-soluble chelators, can readily cross cell membranes and remove intracellular free iron; whereas deferoxamine, which is lipid insoluble, cannot do so. Clinical utility also requires that the chelators be nontoxic, which, we hypothesize, includes the capability to prevent iron from catalyzing free radical reactions which produce •OH or other reactive oxygen species. Lipid-soluble iron chelators currently available for clinical application are bidentate (deferiprone) or tridentate (desferasirox) molecules that do not block all six sites on the iron molecule capable of catalyzing free radical reactions. In contrast, desferri-exochelins are hexadentate molecules, and by forming a one-to-one binding relationship with iron, they prevent free radical reactions. FUTURE DIRECTIONS: Clinical studies are needed to assess the utility of desferri-exochelins in the treatment of iron-dependent pathological disorders.

Indexed as

HumansIron Chelating AgentsIron OverloadMycobacteriumMycobacterium tuberculosisPeptides, CyclicSiderophoresexochelinsIron Chelating AgentsPeptides, CyclicSiderophores

Identifiers

PMID24684595
PMCPMC4224048
OpenAlexW2020313393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.